



ESC

European Society  
of Cardiology

# May Measurement Month 2017: an analysis of blood pressure screening in Spain—Europe

Ana Molinero<sup>1\*</sup>, Luis M. Ruilope<sup>2</sup>, Salvador Tous<sup>1</sup>, José A. Fornos<sup>1</sup>, Inés Mera<sup>1</sup>, Nicanor F. Andrés<sup>1</sup>, Montserrat Iracheta<sup>1</sup>, Xin Xia<sup>3</sup>, Thomas Beaney<sup>3</sup>, Neil R. Poulter<sup>3</sup>, Enrique Rodilla<sup>4</sup>, Fernando Martínez<sup>5</sup>, and Teresa Gijón-Conde<sup>6</sup>

<sup>1</sup>Spanish Society of Community and Family Pharmacy, Madrid, Spain;

<sup>2</sup>Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain;

<sup>3</sup>Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK;

<sup>4</sup>Internal Medicine, University Hospital Sagunto, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain;

<sup>5</sup>Hypertension Unit, Internal Medicine Department, Research Institute of the Clinical Hospital of Valencia (INCLIVA), Valencia, Spain; and

<sup>6</sup>Primary Care Center Cerro del Aire, Majadahonda. Member of the Council of the Spanish Society of Hypertension, Madrid, Spain

---

May Measurement Month 2017 is a global initiative aimed at raising awareness of high blood pressure (BP) and to act as a temporary solution to the lack of screening programs worldwide, in which Spain participated actively. The primary objective was to raise awareness and increase control of BP in Spain. An opportunistic cross-sectional survey of volunteers aged  $\geq 18$  was set up in May 2017. Following the design of the International Society of Hypertension, data were collected from the 17 autonomous communities in which Spain is divided, mainly in community pharmacies, primary care centres and some hypertension (HT) units, and cardiovascular departments in hospitals. No additional training of volunteers was necessary. A total of 3849 individuals were screened. After multiple imputation, our data showed that 1923 (50.0%) had HT. In those not receiving antihypertensive medication, 17.5% were hypertensives, in individuals receiving antihypertensive medication, 33.9% had uncontrolled BP. May Measurement Month 2017 was the largest BP screening campaign undertaken in Spain. In total, 17.5% of people with HT did not receive medication. One-third of hypertensive participants receiving treatment did not have their BP controlled. These results confirm that an opportunistic screening can identify a significant number of subjects with and untreated and inadequately treated BP.

---


## Background

Raised blood pressure (BP) is a growing burden worldwide.<sup>1,2</sup> Hypertension (HT) is the most prevalent chronic disease in Spain. According to the latest national study on Nutrition and Cardiovascular Risk in Spain, performed


on a representative sample of the non-institutionalized population of Spain aged  $\geq 18$  years, 33.3% were hypertensive, 59.4% were aware of their condition, 78.8% were treated among those who were aware, and 48.5% were controlled among those aware and treated (22.7% of all hypertensives).<sup>3</sup> Recent data of The National Statistical Institute report that (HT-related) cardiovascular disease is still the main cause of death in Spain,<sup>4</sup> representing 29.2% of all deaths (32.8% in women and 25.6% in men). Of all deaths in Spain, 7.8% corresponded to ischaemic heart disease, 6.6% to cerebrovascular

---

\*Corresponding author. Tel: +34916074010, Fax: 0034 914354888, Email: anamolinerosefac.org



**Figure 1** Difference in mean blood pressure according to individual characteristics from linear regression model adjusted for age, sex and, antihypertensive medication.



**Figure 2** Difference in mean blood pressure according to body mass index from linear regression model, adjusted for age, sex, and antihypertensive medication, with underweight as the reference category.

disease, 4.3% to heart failure, and 2.9% to hypertensive disease.<sup>5</sup> The aim of May Measurement Month 2017 (MMM17) participation in Spain was to raise awareness, treatment, and control of BP in Spain.

## Methods

The MMM Spain cross-sectional survey was set up between 1st and 31st of May 2017. Volunteers were recruited through the Spanish Society of Hypertension (SEH-LELHA) and the Spanish Society of Community Pharmacy (SEFAC). Communication and distribution of the protocol, essential training material, videos, and marketing information were

shared using the bespoke MMM website. Blood pressure measurements and a questionnaire about demographic, lifestyle, and cardiovascular risk factors, according to the MMM17 protocol, were carried out. Hypertension was defined as systolic BP (SBP)  $\geq 140$  mmHg and/or diastolic BP (DBP)  $\geq 90$  mmHg, or on reported current use of antihypertensive medication. Blood pressure was measured mostly with automated devices and included three seated recordings taken on the left arm. Participants with BP  $\geq 140$  and/or 90 mmHg were provided with printed evidence-based dietary and lifestyle suggestions and advice. Submitted data were analysed centrally by the MMM project team using Stata version 14.2.<sup>3</sup>

## Results

The mean age of the 3849 participants was  $57.4 \pm 16.7$  years, (39.9% males), 39.4% were taking anti-hypertensive medication. In total, 13.0% were diabetics, 4.7% reported a history of myocardial infarction, and 3.4% of stroke. In total, 22.5% declared alcohol consumption once or more per week, 19.8% were smokers, and 1.7% of females declared being pregnant. The mean body mass index was  $26.9 \text{ kg/m}^2 \pm 4.7$ .

Blood pressure decreased on average by 3.7/1.6 mmHg between the first and third BP readings. Multiple imputations were used to calculate the mean of the second and third readings based on any single reading reported.<sup>3</sup> After imputation, of the 3848 individuals for whom data were available or known to be on antihypertensive treatment, 1923 (50.0%) participants were hypertensive. Of participants not on antihypertensive medication, 17.5% were found to have HT, while 513 (33.9%) of 1515 participants receiving treatment had uncontrolled BP.

The age and sex standardized mean BP was 120.6/74.8 mmHg. After adjustment for age and sex, significantly higher BP values in people receiving antihypertensive treatment and lower BP values in those with previous myocardial infarction and previous stroke were found (Figure 1). Systolic BP was higher in those with type 2 diabetes. Alcohol intake was associated with a significant increase in DBP (Figure 1).

Obese people showed significantly higher SBP and DBP while overweighted individuals only had significantly higher SBP (Figure 2).

## Discussion

The Spanish sample was 3.5% of the European sample while, according to the objective, it should have been 9.1%.<sup>4</sup> This discrepancy was probably due to the short preparation time of the campaign. However, the quality of the registry was adequate. The percentage of Spanish hypertensives (39.4%) was higher than previously described in Spain.<sup>3</sup> On the other hand, it was lower than the one described by European countries (55%) and in agreement with the global population (34.9%).<sup>6,7</sup> Systolic BP mean was the same as worldwide and 3.5 mmHg lower than European; DBP was 2.0 mmHg lower than worldwide and 2.5 mmHg lower than European.<sup>6,7</sup>

The frequency of HT in Spanish participants who were not receiving treatment was similar to the frequency in the world population (17.5% and 17.3%, respectively), but lower than in the European population (26.3%). In individuals receiving antihypertensive medication, 33.9% had uncontrolled BP. These data are lower than the proportion of uncontrolled hypertensives worldwide (46.3%) and in the European population (63.6%).<sup>6,7</sup>

## Conclusions

May Measurement Month 2017 was the largest BP screening campaign undertaken in Spain. One-third of hypertensive participants receiving treatment did not have their BP

controlled. These results confirm that opportunistic screening can identify significant numbers of subjects with untreated and inadequately treated BP.

## Acknowledgements

We thank all volunteers and participants.

**Conflict of interest:** none declared.

## References

- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekeef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT-A, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FGR, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang Y-H, Khatibzadeh S, Khoo J-P, Kok C, Laden F, Laloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcesnes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CDH, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJC, Steenland K, Stöckl N, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJL, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;**380**:2224-2260.
- Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Hassen Abate K, Akinemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang Y-H, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shive I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, Zaki MES, Murray CJL. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. *JAMA* 2017;**317**:165-182.
- Banegas JR, Graciani A, de la Cruz-Troca JJ, León-Muñoz LM, Guallar-Castillón P, Coca A, Ruilope LM, Rodríguez-Artalejo F. Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. *Hypertension* 2012;**60**:898-905.
- Defunciones según la causa de la muerte en España. Informe del Instituto Nacional de Estadística 2016. <http://www.ine.es/prensa/np963.pdf> (24 October 2018).

5. Las 15 causas más frecuentes de muerte en España Instituto Nacional de Estadística 2016. [https://public.tableau.com/views/CAUSASDEMUERTE1/Dashboard1?: showVizHome=no&: embed=true](https://public.tableau.com/views/CAUSASDEMUERTE1/Dashboard1?:showVizHome=no&:embed=true) (24 October 2018).
6. Poulter NR, Lackland DT. May Measurement Month: a global blood pressure screening campaign. *Lancet* 2017;**389**:1678-1680.
7. Beaney T, Schutte AE, Tomaszewski M, Ariti C, Burrell LM, Castillo RR, Charchar FJ, Damasceno A, Kruger R, Lackland DT, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Wang J, Weber MA, Poulter NR; MMM Investigators. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. *Lancet Glob Health* 2018; **6**:736-743.